Literature DB >> 10781881

CYP2A6: a human coumarin 7-hydroxylase.

O Pelkonen1, A Rautio, H Raunio, M Pasanen.   

Abstract

Coumarin 7-hydroxylation is catalysed by a high-affinity CYP2A6 enzyme in human liver microsomes. CYP2A6 is the only enzyme catalysing this reaction and consequently the formation of 7-hydroxycoumarin can be used as 'an in vitro and in vivo probe' for CYP2A6. CYP2A6 is a major contributor to the oxidative metabolism of nicotine and cotinine, and it also contributes, to a larger or smaller extent, to the metabolism of a few pharmaceuticals (e.g. fadrozole), nitrosamines, other carcinogens (e.g. aflatoxin B1) and a number of coumarin-type alkaloids. CYP2A6 may be inducible by antiepileptic drugs and it is decreased in alcohol-induced severe liver cirrhosis. Several mutated or deleted CYP2A6 alleles have been characterized. Although CYP2A6 represent up to 15% of human microsomes P450 proteins, it is still one of the less well characterised cytochrome P450 enzymes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781881     DOI: 10.1016/s0300-483x(99)00200-0

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  34 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents.

Authors:  Guannan Li; Charlotte Simmler; Luying Chen; Dejan Nikolic; Shao-Nong Chen; Guido F Pauli; Richard B van Breemen
Journal:  Eur J Pharm Sci       Date:  2017-07-31       Impact factor: 4.384

3.  High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions.

Authors:  Guannan Li; Ke Huang; Dejan Nikolic; Richard B van Breemen
Journal:  Drug Metab Dispos       Date:  2015-08-18       Impact factor: 3.922

4.  Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Authors:  Evan T Ogburn; David R Jones; Andrea R Masters; Cong Xu; Yingying Guo; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-03-24       Impact factor: 3.922

5.  A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.

Authors:  Man Ki Ho; Jill C Mwenifumbo; Bin Zhao; Elizabeth M J Gillam; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

6.  The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Authors:  Robin E Pearce; Michael Cohen-Wolkowiez; Mario R Sampson; Gregory L Kearns
Journal:  Drug Metab Dispos       Date:  2013-06-27       Impact factor: 3.922

7.  Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition.

Authors:  Tsutomu Shimada; Donghak Kim; Norie Murayama; Katsuhiro Tanaka; Shigeo Takenaka; Leslie D Nagy; Lindsay M Folkman; Maryam K Foroozesh; Masayuki Komori; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-03-13       Impact factor: 3.739

8.  Bioactivation of the tobacco carcinogens 4-aminobiphenyl (4-ABP) and 2-amino-9H-pyrido[2,3-b]indole (AαC) in human bladder RT4 cells.

Authors:  Medjda Bellamri; Lihua Yao; Radha Bonala; Francis Johnson; Linda B Von Weymarn; Robert J Turesky
Journal:  Arch Toxicol       Date:  2019-06-15       Impact factor: 5.153

9.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

10.  An experimental verification of the predicted effects of promoter TATA-box polymorphisms associated with human diseases on interactions between the TATA boxes and TATA-binding protein.

Authors:  Ludmila Savinkova; Irina Drachkova; Tatyana Arshinova; Petr Ponomarenko; Mikhail Ponomarenko; Nikolay Kolchanov
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.